GLP-1 Drugs 101: How Ozempic & Friends Work

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates.

The GLP-1 receptor agonist drug class has rewritten the playbook on obesity and type 2 diabetes treatment over the past two decades. From Byetta’s twice-daily injection in 2005 to once-weekly tirzepatide producing approximately 21% body weight loss in clinical trials, this class has progressed faster than almost any therapeutic category in modern medicine.

As of May 2026, the FDA-approved class includes six distinct active ingredients sold under twelve brand names, plus an oral GLP-1 expansion that fundamentally changes the access landscape. This guide covers the complete approved class, the mechanism of action that makes these drugs work, efficacy comparisons across generations, and what the pipeline looks like for the rest of 2026 and beyond.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic glucagon-like peptide-1 (GLP-1), a natural hormone produced by intestinal L-cells in response to food intake. The native GLP-1 hormone was first identified in 1987 and has a half-life of approximately 1-2 minutes — far too short for therapeutic use. GLP-1 receptor agonists are engineered peptide molecules that bind to the same receptor as native GLP-1 but resist enzymatic degradation, allowing once-daily or once-weekly dosing.

The class includes both pure GLP-1 agonists (activating only the GLP-1 receptor) and dual agonists (tirzepatide activates both GLP-1 and GIP receptors). A triple agonist (retatrutide, activating GLP-1, GIP, and glucagon receptors) is in late-stage clinical trials and represents the next evolutionary step.

How GLP-1 Agonists Work

GLP-1 receptor agonists produce their clinical effects through multiple mechanisms operating in parallel:

• Glucose-dependent insulin secretion: GLP-1 receptors on pancreatic beta cells stimulate insulin release in response to elevated blood glucose. Unlike insulin therapy, this mechanism is glucose-dependent — insulin release shuts off when blood sugar normalizes, reducing hypoglycemia risk.
• Glucagon suppression: GLP-1 reduces glucagon secretion from pancreatic alpha cells, lowering hepatic glucose production.
• Delayed gastric emptying: GLP-1 slows the rate at which food leaves the stomach, prolonging satiety and reducing post-meal glucose spikes. This mechanism is also responsible for the most common side effects (nausea, fullness) particularly during titration.
• Central appetite suppression: GLP-1 receptors in the hypothalamus signal satiety and reduce hunger. Patients commonly describe reduced “food noise” — the constant background thoughts about eating that obesity patients often report.
• Direct effects on cardiovascular tissue: Emerging research suggests GLP-1 receptor activation has direct effects on cardiomyocytes, vascular endothelium, and inflammatory markers — independent of weight loss or glycemic improvement.

Tirzepatide’s additional GIP receptor activation amplifies these effects — particularly insulin sensitivity and lipolysis inhibition — which explains its superior weight loss outcomes compared to pure GLP-1 agonists at equivalent doses.

The Complete FDA-Approved GLP-1 Class (May 2026)

Six active ingredients spanning twelve brand names are currently FDA-approved in the GLP-1 class. Listed by first FDA approval date:

Exenatide — Byetta (2005), Bydureon BCise (2017)

• First approval: Byetta — April 28, 2005
• Manufacturer: AstraZeneca (originally Amylin Pharmaceuticals/Lilly)
• Dosing: Byetta twice-daily injection; Bydureon BCise once-weekly
• Indications: Type 2 diabetes
• Notable: First GLP-1 ever approved. Original molecule derived from exendin-4, a peptide found in Gila monster saliva. Largely supplanted by newer weekly options but remains available for patients who respond well.

Liraglutide — Victoza (2010), Saxenda (2014)

• First approval: Victoza — January 25, 2010 (T2D); Saxenda — December 23, 2014 (weight management)
• Manufacturer: Novo Nordisk
• Dosing: Once-daily subcutaneous injection
• Indications: Victoza (T2D, cardiovascular event reduction); Saxenda (chronic weight management)
• Efficacy: First-generation GLP-1 efficacy — approximately 5-8% body weight reduction in obesity trials
• Notable: First GLP-1 specifically approved for weight management. Cardiovascular benefits established in LEADER trial. Daily injection schedule is less convenient than newer weekly options.

Lixisenatide — Adlyxin (2016)

• First approval: Adlyxin — July 27, 2016
• Manufacturer: Sanofi
• Dosing: Once-daily injection
• Indications: Type 2 diabetes
• Notable: Less commonly prescribed than other GLP-1s due to relatively modest efficacy compared to weekly alternatives.

Dulaglutide — Trulicity (2014)

• First approval: Trulicity — September 18, 2014
• Manufacturer: Eli Lilly
• Dosing: Once-weekly injection
• Indications: Type 2 diabetes plus reduction of major adverse cardiovascular events in adults with T2D and established CV disease
• Efficacy: Modest weight loss (~3-5%) — primarily prescribed for glycemic control rather than weight management
• Notable: First once-weekly GLP-1 in routine clinical use. REWIND trial established cardiovascular outcome benefits.

Semaglutide — Ozempic (2017), Rybelsus (2019), Wegovy (2021), Wegovy Oral (2025)

• First approval: Ozempic — December 5, 2017 (T2D)
• Manufacturer: Novo Nordisk
• Dosing:
  • Ozempic — once-weekly injection (T2D)
  • Rybelsus — once-daily oral tablet (T2D)
  • Wegovy — once-weekly injection (chronic weight management)
  • Wegovy Oral — once-daily tablet (chronic weight management) — approved December 2025
• Efficacy: Approximately 15% body weight reduction at maximum maintenance dose (2.4 mg weekly injectable). STEP-1 trial demonstrated -14.9% body weight at 68 weeks vs -2.4% placebo. Second-generation efficacy.
• Cardiovascular benefits: SELECT trial established 20% reduction in major adverse cardiovascular events (MACE) in patients with established CVD and overweight/obesity but without diabetes.
• Notable: The most extensively studied GLP-1 in clinical use. Tested in SUSTAIN (diabetes), STEP (weight loss), PIONEER (oral), and SELECT (cardiovascular) trial programs. The first GLP-1 to demonstrate cardiovascular benefit in non-diabetic patients.

Tirzepatide — Mounjaro (2022), Zepbound (2023)

• First approval: Mounjaro — May 13, 2022 (T2D)
• Manufacturer: Eli Lilly
• Dosing:
  • Mounjaro — once-weekly injection (T2D)
  • Zepbound — once-weekly injection (chronic weight management, approved November 8, 2023; OSA approval added December 2024)
• Efficacy: -15% to -21% body weight reduction depending on dose. SURMOUNT-1 trial demonstrated -15.0% (5mg), -19.5% (10mg), and -20.9% (15mg) at 72 weeks. Dual-agonist efficacy.
• Mechanism distinction: Activates both GLP-1 and GIP receptors. This dual mechanism produces additive effects beyond pure GLP-1 agonism — particularly enhanced insulin sensitivity, lipolysis inhibition, and weight loss.
• Notable: First dual GIP/GLP-1 receptor agonist. December 2024 approval for obstructive sleep apnea (Zepbound) made tirzepatide the first pharmacotherapy approved for moderate-to-severe OSA in adults with obesity. SURPASS trial program established T2D efficacy; SURMOUNT program established obesity efficacy.

Approved Uses Across the GLP-1 Class

The clinical indications for GLP-1 medications have expanded substantially as evidence has accumulated. As of May 2026, FDA-approved uses include:

Type 2 Diabetes

All major GLP-1 RAs are approved as adjuncts to diet and exercise for glycemic control in adults with type 2 diabetes. They can be used as monotherapy or in combination with metformin, SGLT2 inhibitors, sulfonylureas, or insulin. Specific approved formulations: Ozempic, Mounjaro, Trulicity, Bydureon BCise, Byetta, Victoza, Adlyxin, Rybelsus.

Chronic Weight Management

Approved formulations specifically indicated for weight loss in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities:

• Saxenda (liraglutide) — December 2014
• Wegovy injectable (semaglutide) — June 2021
• Zepbound (tirzepatide) — November 2023
• Wegovy oral (semaglutide tablets) — December 2025

Cardiovascular Risk Reduction

Specific GLP-1s have FDA-approved indications for reducing major adverse cardiovascular events (MACE):

• Trulicity (dulaglutide): MACE reduction in adults with T2D and established CV disease
• Victoza (liraglutide): MACE reduction in adults with T2D and CV disease (LEADER trial)
• Ozempic (semaglutide): MACE reduction in adults with T2D and established CV disease
• Wegovy (semaglutide): MACE reduction in adults with established CV disease and overweight/obesity (without diabetes) — based on SELECT trial 20% MACE reduction

Obstructive Sleep Apnea

Zepbound (tirzepatide) received FDA approval December 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first pharmacotherapy ever approved for this indication. Approval was based on the SURMOUNT-OSA trial showing tirzepatide significantly reduced apnea-hypopnea events compared to placebo, both in patients using CPAP and those not using CPAP.

Off-Label and Investigational Uses

Active research is exploring GLP-1 agonists for indications not yet FDA-approved:

• Heart failure with preserved ejection fraction (HFpEF): Subanalysis of SELECT trial showed semaglutide improved heart failure outcomes in patients with HFpEF and obesity. STEP-HFpEF trial established symptomatic improvement.
• Chronic kidney disease: TREASURE-CKD trial (expected completion October 2026) evaluating tirzepatide in obesity with CKD.
• Peripheral artery disease: Emerging trials in adults with PAD.
• Alzheimer’s disease and neurodegenerative conditions: Multiple Phase 3 trials investigating GLP-1 effects on cognitive decline.
• Addiction (alcohol use disorder, nicotine, opioid): Early research suggests GLP-1 agonists may reduce reward-driven consumption behaviors.
• PCOS: Off-label use for polycystic ovary syndrome related insulin resistance and weight management.

The Generations of GLP-1 Therapy

The progression of GLP-1 therapy reflects iterative improvements in molecular engineering and receptor targeting. Each generation has delivered meaningfully greater weight loss outcomes than the previous:

• First generation — Pure GLP-1, short-acting: Exenatide (Byetta), liraglutide (Victoza, Saxenda). Daily or twice-daily dosing. Weight loss ~5-8% in obesity trials. Established proof of concept.
• Second generation — Pure GLP-1, long-acting: Semaglutide (Ozempic, Wegovy, Rybelsus, Wegovy oral), dulaglutide (Trulicity). Weekly or once-daily oral dosing. Weight loss approximately 15% in obesity trials at maximum dose. Cardiovascular benefits firmly established.
• Dual agonists — GLP-1 + GIP: Tirzepatide (Mounjaro, Zepbound). Weekly dosing. Weight loss approximately 15-21% depending on dose. Expanded indication into OSA. Currently the most efficacious GLP-1-based therapy in clinical use.
• Triple agonists (pipeline) — GLP-1 + GIP + glucagon: Retatrutide (Eli Lilly). Phase 3 trials. Early data shows ~24%+ weight loss with curves still trending downward at trial endpoints. Not yet FDA-approved.
• Amylin combinations (pipeline): CagriSema (cagrilintide + semaglutide, Novo Nordisk). FDA response expected in 2026. Combines amylin agonism with GLP-1 receptor agonism.

Side Effects — Class Profile

The GLP-1 class shares a consistent side effect profile across all approved medications, driven primarily by the mechanism’s effect on the gastrointestinal system. Side effects typically peak during titration and improve with dose stability:

Common Side Effects

• Gastrointestinal: Nausea (most common across all GLP-1s), vomiting, diarrhea, constipation, abdominal pain
• Decreased appetite: Central mechanism of weight loss — not technically a side effect but the intended effect
• Fatigue: Common during early titration weeks
• Injection site reactions: Minor redness or itching at injection site
• Hair shedding: Reported anecdotally, typically associated with rapid weight loss rather than direct medication effect
• “Ozempic face”: Facial volume loss from rapid weight reduction — cosmetic, not a direct medication effect

Less Common but Serious

• Pancreatitis: Rare but reported across the class. Discontinue if suspected.
• Gallbladder disease: Increased risk of gallstones, particularly with rapid weight loss.
• Acute kidney injury: Usually associated with severe vomiting and dehydration during titration.
• Severe gastroparesis: Delayed gastric emptying that becomes clinically significant — may require medication discontinuation.
• Hypoglycemia: Rare with GLP-1 monotherapy due to glucose-dependent mechanism. Risk increases significantly when combined with insulin or sulfonylureas.

Black Box Warning

All GLP-1 medications carry an FDA black box warning regarding thyroid C-cell tumors observed in rodent studies. Do not use GLP-1 agonists if you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The clinical relevance of rodent thyroid findings to humans remains uncertain, but the warning applies across the entire class.

For comprehensive side effect management strategies, see: GLP-1 Side Effects: Complete Survival Guide.

Cost and Access in 2026

GLP-1 pricing varies dramatically depending on the specific medication, indication, insurance coverage, and access pathway. The May 2026 landscape:

Brand-Name Pricing (Cash Pay, May 2026)

• Wegovy injectable: ~$1,349/month list price
• Wegovy oral (Hims/Ro authorized distributors): $149/month
• Ozempic: ~$968/month list price; widely covered by insurance for T2D
• Mounjaro: ~$1,023/month list price; widely covered for T2D
• Zepbound (LillyDirect Self Pay): $299/month (2.5 mg), $399 (5 mg), $449 (7.5-15 mg with 45-day refill compliance)
• Saxenda (liraglutide): ~$1,349/month — limited demand given superior alternatives
• Rybelsus (oral semaglutide tablets): ~$1,000/month list price
• Trulicity: ~$900-$1,000/month list price

Insurance and Savings Programs

• Commercial insurance with weight management coverage: Patient cost typically $25-$50/month with manufacturer savings cards (Lilly Zepbound savings, Novo Nordisk Wegovy savings)
• Commercial insurance without weight management coverage: Most plans cover T2D-indicated GLP-1s (Ozempic, Mounjaro) but deny obesity-indicated formulations (Wegovy, Zepbound). Manufacturer programs offer $499/month for unmarried denials.
• Medicare: Standard Part D excludes weight loss medications. Medicare GLP-1 Bridge launches July 1, 2026 — will cover Zepbound KwikPen at $50/month for qualifying beneficiaries (BMI ≥35, or BMI ≥27 with weight-related comorbidities).
• Patient assistance programs: Both Eli Lilly and Novo Nordisk offer income-qualified patient assistance for patients without coverage. Eligibility requirements are strict.

Compounded GLP-1 Pricing

• Compounded semaglutide: $99-$297/month through 503A telehealth providers (Trimi, Ro, Henry Meds, Noom, Direct Meds, etc.)
• Compounded tirzepatide: $279-$499/month where legally available (narrow 503A medical necessity exceptions only after February-March 2025 enforcement deadlines)

For detailed pricing analysis, see: GLP-1 Cost Without Insurance: 2026 Reality Check.

The Compounded GLP-1 Landscape in 2026

Compounded versions of GLP-1 medications have been a significant access pathway since 2022, when the FDA added semaglutide and tirzepatide to the drug shortage list. At peak in 2024, compounded GLP-1s reached approximately 30% of US semaglutide supply. The regulatory environment has shifted substantially since then.

• Compounded semaglutide: Remains legal through 503A patient-specific compounding pharmacies in May 2026. The April 30, 2026 FDA proposed rule excludes semaglutide from the 503B Bulks List, but 503A pathway access continues.
• Compounded tirzepatide: Available only through narrow 503A medical necessity exceptions (documented polysorbate 80 allergy, non-standard dose or route, combination formulations with clinical significance). Shortage resolved December 19, 2024; enforcement discretion ended February 18, 2025 (503A) and March 19, 2025 (503B).
• Compounded liraglutide: Still on FDA shortage list as of May 2026, retaining broader compounding authority.

For patients researching access to compounded GLP-1s, two detailed guides cover the current regulatory landscape:

• Compounded Semaglutide: The Complete 2026 Guide
• Compounded Tirzepatide in 2026: What’s Legal, What’s Not

“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process.”

Dr. Marty Makary, FDA Commissioner — April 30, 2026

Pipeline and Future of GLP-1 Therapy

The GLP-1 development pipeline remains exceptionally active in 2026, with multiple candidates progressing through late-stage trials:

Near-Term Approvals Expected

• Orforglipron (Eli Lilly): First oral once-daily small molecule GLP-1 receptor agonist. Phase 3 data showed weight loss approximately comparable to oral semaglutide. Expected FDA action in 2026. Pricing anticipated around $149/month for the lowest dose.
• CagriSema (Novo Nordisk): Combination of cagrilintide (amylin agonist) and semaglutide. Phase 3 data in REDEFINE trial program showed weight loss in obesity exceeding semaglutide monotherapy. FDA response expected in 2026.

Phase 3 Pipeline

• Retatrutide (Eli Lilly): Triple agonist activating GLP-1, GIP, and glucagon receptors. Phase 2 data showed approximately 24% weight loss at 48 weeks — with weight loss curves still trending downward at study end, suggesting maximum effect not yet reached. Phase 3 trials ongoing.
• Survodutide (Boehringer Ingelheim/Zealand Pharma): Dual GLP-1/glucagon receptor agonist. Phase 3 in obesity and NASH.
• Pemvidutide (Altimmune): Dual GLP-1/glucagon receptor agonist. Phase 2 obesity trials.

Expanded Indications Under Investigation

• Heart failure (with reduced ejection fraction and preserved ejection fraction)
• Chronic kidney disease
• Peripheral artery disease
• Alzheimer’s disease and cognitive decline
• Alcohol use disorder and other addiction conditions
• Non-alcoholic steatohepatitis (NASH)
• Polycystic ovary syndrome (PCOS)
• Postmenopausal weight gain and metabolic syndrome

Frequently Asked Questions

What’s the difference between Ozempic, Wegovy, and Rybelsus?

All three contain semaglutide as the active ingredient. Ozempic and Wegovy are injectable formulations — Ozempic is FDA-approved for type 2 diabetes (lower max dose, 2.0 mg weekly), Wegovy for chronic weight management (higher max dose, 2.4 mg weekly). Rybelsus is an oral tablet formulation of semaglutide, approved for type 2 diabetes only. December 2025 brought the first oral semaglutide approved for weight management (Wegovy oral tablets).

What’s the difference between Mounjaro and Zepbound?

Both contain tirzepatide as the active ingredient at identical doses. The distinction is FDA indication: Mounjaro is approved for type 2 diabetes (May 2022), Zepbound is approved for chronic weight management (November 2023) and obstructive sleep apnea (December 2024). Insurance plans typically cover Mounjaro for diabetic patients but deny Zepbound coverage even though the medications are chemically identical.

Are tirzepatide and semaglutide both GLP-1 agonists?

Technically, tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide is a pure GLP-1 receptor agonist. Tirzepatide activates both the GLP-1 receptor (like semaglutide) and additionally the GIP receptor, which produces additive metabolic effects. In clinical conversation and most medical literature, tirzepatide is grouped with the GLP-1 class because GLP-1 is one of its primary mechanisms.

Which GLP-1 produces the most weight loss?

Among FDA-approved options in May 2026, tirzepatide 15 mg has produced the highest weight loss in clinical trials — approximately 20.9% body weight reduction at 72 weeks in SURMOUNT-1. Semaglutide 2.4 mg (Wegovy) achieves approximately 14.9% at 68 weeks. Investigational triple agonists (retatrutide) have shown approximately 24%+ in earlier-phase trials but are not yet FDA-approved.

Are GLP-1 medications safe long-term?

Long-term safety data continues to accumulate. The longest follow-up data comes from semaglutide trials extending to 4 years (SELECT trial 208-week analysis) showing sustained weight loss and reduced cardiovascular events with no new safety signals. Liraglutide has been in clinical use since 2010 with no major safety concerns emerging. The black box warning for thyroid tumors remains based on rodent studies; human relevance is uncertain after more than a decade of clinical use.

Can I stop taking GLP-1 medications after reaching my weight goal?

Clinical trial data suggests significant weight regain when GLP-1 medications are discontinued. The STEP-4 trial demonstrated substantial regain of lost weight after semaglutide cessation. Most obesity medicine specialists view GLP-1 therapy as long-term or indefinite treatment for chronic obesity — similar to how insulin or blood pressure medications are typically lifelong.

Why are GLP-1 medications so expensive?

GLP-1 medications are complex peptide molecules that require specialized manufacturing processes. Demand has consistently exceeded supply since 2022, sustaining high prices. Both Eli Lilly and Novo Nordisk hold extensive patents on their molecules, limiting generic competition until late this decade. Cash-pay programs (LillyDirect, Novo Nordisk programs) have reduced effective pricing substantially over 2024-2026.

What’s the difference between liraglutide (Saxenda) and semaglutide (Wegovy)?

Both are GLP-1 receptor agonists from Novo Nordisk for chronic weight management. Liraglutide (Saxenda) is daily injection, approved 2014, produces ~5-8% body weight reduction. Semaglutide (Wegovy) is weekly injection, approved 2021, produces ~15% weight reduction. Wegovy has largely supplanted Saxenda in clinical practice due to better efficacy and weekly dosing convenience.

Are there pill forms of GLP-1?

Yes. Rybelsus (oral semaglutide tablets) has been approved since 2019 for type 2 diabetes. Wegovy oral tablets received FDA approval December 2025 for chronic weight management — the first oral GLP-1 specifically approved for weight loss. Orforglipron (Eli Lilly) — an oral small-molecule GLP-1 — is expected to receive FDA action in 2026, anticipated to be the first non-peptide oral GLP-1.

Will Medicare cover GLP-1 medications in 2026?

Standard Medicare Part D excludes weight loss medications. Medicare does cover GLP-1s with established indications other than weight loss — diabetes (Ozempic, Mounjaro), cardiovascular risk reduction (Wegovy for CV indication). The Medicare GLP-1 Bridge program launches July 1, 2026, providing $50/month Zepbound KwikPen access for qualifying Medicare beneficiaries with BMI ≥35 (or BMI ≥27 with weight-related comorbidities).

The Bottom Line for May 2026

The GLP-1 receptor agonist class has matured rapidly from its first approval in 2005 into one of the most consequential medication categories in modern medicine. Six FDA-approved active ingredients across twelve brand names provide patients and prescribers a wide spectrum of options — from daily oral tablets to weekly injections, from modest weight loss for first-generation drugs to approximately 21% body weight reduction with current dual agonists.

The 2026 landscape combines exceptional clinical efficacy with substantial access challenges. Cash-pay program improvements (LillyDirect Zepbound at $299-449/month, Wegovy oral at $149/month) have made brand-name GLP-1s more accessible than at any point since their introduction. The compounded GLP-1 market — while substantially restricted for tirzepatide after early 2025 enforcement deadlines — remains a legitimate access pathway for semaglutide through 503A compounding pharmacies.

For patients exploring GLP-1 therapy, the practical decision framework in 2026:

• Type 2 diabetes with insurance coverage: Brand-name Ozempic or Mounjaro through insurance is typically the most cost-effective and clinically established path.
• Obesity targeting moderate weight loss (10-15%): Compounded semaglutide via legitimate 503A telehealth providers offers cost-effective access — covered in detail in the compounded semaglutide guide.
• Obesity targeting maximum weight loss (20%+): Brand-name Zepbound through LillyDirect Self Pay Journey Program at $299-449/month, or tirzepatide medical necessity compounding if criteria met.
• Established cardiovascular disease: Wegovy for non-diabetic patients (FDA-approved CV indication based on SELECT trial), or Ozempic for diabetic patients.
• OSA with obesity: Zepbound (only FDA-approved pharmacotherapy for moderate-to-severe OSA in adults with obesity, approved December 2024).
• Oral preference: Wegovy oral tablets (December 2025), Rybelsus for diabetes, or wait for orforglipron approval in 2026.

The class will continue to evolve through 2026 and beyond, with triple agonists pushing weight loss outcomes higher, expanded indications opening new therapeutic applications, and oral formulations broadening access. The fundamentals — appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion — remain the foundation that has made GLP-1 receptor agonists the defining metabolic medication class of this decade.